Europe Upstream Bioprocessing Market Forecast to 2030 - Regional Analysis by Product Type, Workflow, Usage Type, and Mode

Outsourcing of Biopharmaceutical Manufacturing Drives Europe Upstream Bioprocessing Market

Europe Upstream Bioprocessing Market Overview

Europe Upstream Bioprocessing Market Segmentation

• The Europe upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country. Based on product type, the Europe upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters services held the largest market share in 2022.
• Based on workflow, the Europe upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
• Based on usage type, the Europe upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022
• Based on mode, the Europe upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house held a larger market share in 2022.
• Based on country, the Europe upstream bioprocessing market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe upstream bioprocessing market share in 2022.
• Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Cellexus International Ltd, Sartorius AG, Getinge AB, Merck KGaA, Corning Inc, and Entegris Inc are some of the leading companies operating in the Europe upstream bioprocessing market.

Market Highlights

• Based on product type, the Europe upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.0% market share in 2022, amassing US$ 902.31 million. It is projected to garner US$ 2.44 billion by 2030 to expand at 13.3% CAGR during 2022-2030.
• The cell separation segment held 41.2% share of Europe upstream bioprocessing market in 2022, amassing US$ 1.06 billion. It is projected to garner US$ 3.01 billion by 2030 to expand at 13.9% CAGR during 2022-2030.
• The single-use segment held 55.1% share of Europe upstream bioprocessing market in 2022, amassing US$ 1.42 billion. It is projected to garner US$ 3.98 billion by 2030 to expand at 13.7% CAGR during 2022-2030.
• In terms of mode, the Europe upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 53.9% share of Europe upstream bioprocessing market in 2022, amassing US$ 1.39 billion. It is projected to garner US$ 3.71 billion by 2030 to expand at 13.1% CAGR during 2022-2030.
• This analysis states that Germany captured 25.4% share of Europe upstream bioprocessing market in 2022. It was assessed at US$ 655.72 million in 2022 and is likely to hit US$ 1.84 billion by 2030, exhibiting a CAGR of 13.8% during 2022-2030.
• In December 2023, Merck has acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. Merck's upstream therapeutic protein portfolio is boosted by the purchase, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies.
• In October 2023, Getinge AB acquired High Purity New England, Inc for US$ 120 million. By the end of 2024, the company will fully integrate High Purity New England, Inc. The acquisition has helped Getinge AB acquire a comprehensive range of proprietary and distributed products from drug discovery, upstream and downstream processing, and fill-and-finish.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe upstream bioprocessing market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Europe upstream bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.